A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PTG-200 in Normal Healthy Male Volunteers
Latest Information Update: 14 Nov 2019
At a glance
- Drugs PTG 200 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Acronyms PTG-200-01
- Sponsors Protagonist Therapeutics
- 06 Nov 2019 According to a Protagonist Therapeutics media release, data from the study were recently presented at the United European Gastroenterology Week conference and the American College of Gastroenterology (ACG) Annual Scientific Meeting.
- 01 Oct 2019 According to a Protagonist Therapeutics media release, data from the study will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2019.
- 01 Oct 2019 According to a Protagonist Therapeutics media release, data from the study will be presented at the UEG Week 2019 Meeting.